A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.
Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients. Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear. We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy. We described the special clinical course of the patient. Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.
Ahn
J H
JH
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Kim
T H
TH
Peck
K R
KR
Song
Y W
YW
D001327:Autoimmune Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects*; D017285:Polymyositis / Q000139:chemically induced*
D010396:Penicillamine